Login
$CMPX
$0.69 +$0.03 (4.07%) After hours

$CMPX SEC Filings

Filed On Filing
10 Nov 2026 SCHEDULE 13G
09 Nov 2026 FORM 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today ...

02 Oct 2026 Form 4: Lerner Neil, Chief Accounting Officer

Bought 20,000 shares ($18.4K)

25 Sep 2026 Form 4: Lerner Neil, Chief Accounting Officer

Bought 2,500 shares ($2.85K)

22 Sep 2026 8-K: Regulation FD Disclosure

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today...

14 Aug 2026 SCHEDULE 13G/A
07 Aug 2026 SCHEDULE 13G
06 Aug 2026 FORM 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today ...

01 Jul 2026 8-K: Regulation FD Disclosure

1 Nasdaq: CMPX Bringing Transformative Oncology Therapies to Patients Corporate Presentation I July 2026

23 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the...

11 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 10, 2026 Compass Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders. The final results for each of the matters submitted to a vote of stockholders at the meeting are set forth below. A more detailed descri...

15 May 2026 SCHEDULE 13G/A
05 May 2026 FORM 10-Q
05 May 2026 8-K: Results of Operations and Financial Condition

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today r...

30 Apr 2026 Form 4/A: Anderman Jonathan, General Counsel

Bought 25,000 shares ($47.3K)

30 Apr 2026 Form 4/A: Lerner Neil, Chief Accounting Officer

Bought 15,000 shares ($28.4K)

29 Apr 2026 Form 4: Anderman Jonathan, General Counsel

Received 25,000 shares as a grant or award ($47.3K)

29 Apr 2026 Form 4: Lerner Neil, Chief Accounting Officer

Received 15,000 shares as a grant or award ($28.4K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support